VivoSeq
Other

Tympanic Membrane Perforation

2

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Tympanic Membrane Perforation is an early-stage landscape with 2 programs across 2 companies. The most active players are Ebubekir Toprak, Astellas.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Ebubekir Toprak

1 program

PreclinicalAstellas logo

Astellas

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical2

Fibroblast Growth Factor 2

D. Bradley Welling, MD, PhD

Saline Control

D. Bradley Welling, MD, PhD

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

5

clinical trials

Terminated2 · 40%
Completed2 · 40%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)
Terminated·Astellas logoAstellas·Phase 1/2·NCT04305184·36 enrolled
Efficacy of Platelet Enriched Plasma in Preventing Surgery for Patients With Chronic Tympanic Membrane Perforation
Terminated·UUniversity of Kansas Medical Center·Phase 1/2·NCT03837665·1 enrolled
Comparison of Myringoplasty Using Porcine Small Intestinal Submucosa (Biodesign) Versus Autologous Grafts (Perichondrium, Temporalis Fascia, Cartilage, or Fat) for Tympanic Membrane Perforation Closure: A Retrospective Cohort Study
Completed·WWolfson Medical Center·N/A·NCT07698171·60 enrolled
Intraoperative Use of Platelet-Rich Plasma in Tympanoplasty: Effects on Graft Success and Audiological Outcomes - A Prospective Controlled Trial
Completed·—·Preclinical·NCT07664319·48 enrolled
In-office Repair of Chronic Tympanic Membrane Perforations
Active, not recruiting·DD. Bradley Welling, MD, PhD·Preclinical·NCT06448039·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)